Inclusion Criteria:  The eligible population will include pregnant women and their offspring residing in the US and its territories who are exposed to MenQuadfi® during their pregnancy or within 30 days prior to their LMP, for whom the exposure is reported to the pregnancy registry.  Reports of MenQuadfi® pregnancy exposure must contain the following information:  Sufficient evidence to confirm that vaccination occurred during the pregnancy or in the 30 days preceding the LMP; Vaccine name (brand or generic) is provided (i.e., MenQuadfi®, Meningococcal vaccine, MenACWY conjugate vaccine), or not specified (eg, meningococcal vaccine from an unknown manufacturer).  Exclusion Criteria:  Only post-marketing spontaneous case reports will be included; reports from clinical trials will not be part of the registry.  The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.